Literature DB >> 8762060

Detection of alpha 1-adrenoceptor subtypes in human hypertrophied prostate by in situ hybridization.

N Moriyama1, S Kurimoto, S Horie, K Nasu, T Tanaka, K Yano, H Hirano, G Tsujimoto, K Kawabe.   

Abstract

Adrenergic stimulation induces contraction of hypertrophied prostatic tissue via the alpha 1 adrenoceptor, and the results of pharmacological studies suggested the existence of adrenoceptor subtypes. Recently three subtypes (alpha 1a, alpha 1b, and alpha 1d) were cloned. Using probes for these subtypes, we demonstrated their expression in the tissues of ten cases of benign prostatic hypertrophy, using in situ hybridization. To determine the ratio between these subtypes, an RNase protection assay was also performed in three cases. Expression of the alpha 1a and alpha 1d adrenoceptors was diffuse in the smooth muscles of the interstitium, but was absent in glandular epithelial cells. On the contrary, the alpha 1b adrenoceptor was hardly detectable. The RNase protection assay confirmed the absence of the alpha 1b adrenoceptor, the ratio of alpha 1a and alpha 1d being 4:1. These results supported the idea that the differences in prostatic contractile response to several adrenergic drugs are based on the affinities of these drugs for the different subtypes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8762060     DOI: 10.1007/bf02409016

Source DB:  PubMed          Journal:  Histochem J        ISSN: 0018-2214


  20 in total

1.  Cloning, functional expression and tissue distribution of human cDNA for the alpha 1C-adrenergic receptor.

Authors:  A Hirasawa; K Horie; T Tanaka; K Takagaki; M Murai; J Yano; G Tsujimoto
Journal:  Biochem Biophys Res Commun       Date:  1993-09-15       Impact factor: 3.575

Review 2.  Alpha 1-adrenoceptor classification: sharpening Occam's razor.

Authors:  A P Ford; T J Williams; D R Blue; D E Clarke
Journal:  Trends Pharmacol Sci       Date:  1994-06       Impact factor: 14.819

3.  Cloning, expression and characterization of human alpha adrenergic receptors alpha 1a, alpha 1b and alpha 1c.

Authors:  D H Weinberg; P Trivedi; C P Tan; S Mitra; A Perkins-Barrow; D Borkowski; C D Strader; M Bayne
Journal:  Biochem Biophys Res Commun       Date:  1994-06-30       Impact factor: 3.575

4.  Characterization of alpha 1-adrenergic receptor subtypes in rat brain: a reevaluation of [3H]WB4104 and [3H]prazosin binding.

Authors:  A L Morrow; I Creese
Journal:  Mol Pharmacol       Date:  1986-04       Impact factor: 4.436

5.  Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate.

Authors:  D T Price; D A Schwinn; J W Lomasney; L F Allen; M G Caron; R J Lefkowitz
Journal:  J Urol       Date:  1993-08       Impact factor: 7.450

6.  The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype.

Authors:  C Forray; J A Bard; J M Wetzel; G Chiu; E Shapiro; R Tang; H Lepor; P R Hartig; R L Weinshank; T A Branchek
Journal:  Mol Pharmacol       Date:  1994-04       Impact factor: 4.436

7.  Comparison of cloned and pharmacologically defined rat tissue alpha 1-adrenoceptor subtypes.

Authors:  M C Michel; P A Insel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-08       Impact factor: 3.000

8.  A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia.

Authors:  H Lepor; S Auerbach; A Puras-Baez; P Narayan; M Soloway; F Lowe; T Moon; G Leifer; P Madsen
Journal:  J Urol       Date:  1992-11       Impact factor: 7.450

9.  Use of recombinant alpha 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy.

Authors:  R Foglar; K Shibata; K Horie; A Hirasawa; G Tsujimoto
Journal:  Eur J Pharmacol       Date:  1995-01-16       Impact factor: 4.432

10.  Cloning of the human alpha 1d-adrenergic receptor and inducible expression of three human subtypes in SK-N-MC cells.

Authors:  T A Esbenshade; A Hirasawa; G Tsujimoto; T Tanaka; J Yano; K P Minneman; T J Murphy
Journal:  Mol Pharmacol       Date:  1995-05       Impact factor: 4.436

View more
  5 in total

Review 1.  Silodosin in the treatment of benign prostatic hyperplasia.

Authors:  Maxime Rossi; Thierry Roumeguère
Journal:  Drug Des Devel Ther       Date:  2010-10-27       Impact factor: 4.162

Review 2.  Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate.

Authors:  Martin C Michel; Wim Vrydag
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 3.  Mechanistic insights into the role of alpha1adrenergic receptors in lower urinary tract symptoms.

Authors:  Gregory A Michelotti; Debra A Schwinn
Journal:  Curr Urol Rep       Date:  2004-08       Impact factor: 2.862

Review 4.  Management of benign prostatic hyperplasia with silodosin.

Authors:  Tomonori Yamanishi; Tomoya Mizuno; Takao Kamai; Ken-Ichiro Yoshida; Ryuji Sakakibara; Tomoyuki Uchiyama
Journal:  Open Access J Urol       Date:  2009-08-20

5.  Alpha 1-adrenoceptor blocker may improve not only voiding but also storage lower urinary tract symptoms caused by (125) I brachytherapy for prostate cancer.

Authors:  Nobuyuki Oyama; Yoshitaka Aoki; Hideaki Ito; Yoshiji Miwa; Hironobu Akino; Yoshitaka Sato; Hiroki Shioura; Hirohiko Kimura; Osamu Yokoyama
Journal:  ISRN Urol       Date:  2014-03-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.